400 Alexander Park
Princeton, NJ 08540
646 768 9780
Full-time employees: 194
|Ms. Elizabeth A. Barrett||Pres, CEO & Director||1.12M||N/A||1962|
|Mr. Dong Kim||Chief Financial Officer||546.68k||N/A||1977|
|Mr. Jason Drew Smith||Gen. Counsel, Chief Compliance Officer & Corp. Sec.||717.58k||N/A||1972|
|Vincent I. Perrone||Sr. Director of Investor Relations||N/A||N/A||N/A|
|Mr. Eric Van Zanten||Sr. Director of Communications||N/A||N/A||N/A|
|Dr. Sari Prutchi-Sagiv Ph.D.||Marketing Director||N/A||N/A||N/A|
|Dr. Marina Konorty||Exec. VP of R&D and Technical Operations||N/A||N/A||N/A|
|Dr. Mark P. Schoenberg M.D.||Chief Medical Officer||N/A||N/A||1958|
|Mr. Jeffrey Bova M.B.A.||Chief Commercial Officer||N/A||N/A||N/A|
|Mr. James Ottinger R.ph.||Exec. VP of Regulatory Affairs & Quality||N/A||N/A||N/A|
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
UroGen Pharma Ltd.’s ISS governance QualityScore as of 1 June 2023 is 6. The pillar scores are Audit: 8; Board: 3; Shareholder rights: 1; Compensation: 10.